Vilobelimab, CAS 2250440-41-4

Product Description: Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc[1].

Applications: COVID-19-anti-virus

Formula: N/A

References: [1]Michael Bauer, et al. Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study). Crit Care Explor. 2021 Nov 17;3(11):e0577.

CAS Number: 2250440-41-4

Molecular Weight: N/A

Compound Purity: 99.27

Research Area: Infection; Inflammation/Immunology

Solubility: 10 mM in DMSO

Target: Complement System;SARS-CoV

• Artikelnummer: MEXHY-P99520-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99520-10
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated